PharmiWeb.com - Global Pharma News & Resources
15-Oct-2019

Xlife Sciences AG: New project in the portfolio


DGAP-Media / 15.10.2019 / 07:30

Xlife Sciences AG invests in Laxxon Medical AG

We are pleased to announce that Xlife Sciences AG has added Laxxon Medical AG to the portfolio.

Laxxon Medical AG

Laxxon Medical AG owns the exclusive global rights for development, production, and commercialization of an innovative new drug delivery system for the controlled release of pharmaceutical actives. This new process is based on a patented 3D printing process. The aim of Laxxon Medical AG is to grant sub-licenses of this new technology to selected companies in the pharmaceutical industry.

As part of the collaboration, Laxxon Medical AG will also support these companies with their own in-house expertise. They will help the selected companies find new opportunities to extend patent protection of existing products by protecting them from counterfeit products in the market. Laxxon Medical AG collaborates with internationally renowned research institutes and universities.
For more information, please visit: www.laxxon-medical.com.

Xlife Life Sciences AG

Xlife Sciences AG is a Swiss company with focus on investing in promising technologies in the life science industry. Xlife Sciences AG is building the bridge from research and development to healthcare markets by supporting researchers and entrepreneurs in positioning, structuring, developing and implementing their concepts. Together with industrial partners or universities, Xlife Sciences AG leads projects through the proof-of-concept phase after an invention disclosure or start-up. Subsequently, the firm focuses on out-licensing or selling the company, often with a combination of a strategic partnership. Xlife Sciences AG offers its investors direct access to the further development of innovative and future-oriented technologies at a very early stage.
For more information, please visit: www.xlifesciences.ch.



End of Media Release


Issuer: Xlife Sciences AG
Key word(s): Enterprise

15.10.2019 Dissemination of a Press Release, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Xlife Sciences AG
Klausstrasse 19
8008 Z├╝rich
Switzerland
Phone: 0041 44 385 84 60
E-mail: info@xlifesciences.ch
Internet: www.xlifesciences.ch
ISIN: CH0461929603
Listed: Regulated Unofficial Market in Munich
EQS News ID: 890019

 
End of News DGAP Media

Editor Details

Last Updated: 15-Oct-2019